|
Active substance |
romiplostim |
|
Holder |
Amgen |
|
Status |
closed |
|
Indication |
Treatment of adult patients with Primary Immune thrombocytopenia (ITP) within the first 12 months of diagnosis who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) |
|
Public documents |
|
|
Last update |
11/08/2022 |
Nplate®
Last updated on